Braidwell LP Purchases 467,401 Shares of Harrow, Inc. (NASDAQ:HROW)

Braidwell LP increased its position in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 106.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 907,039 shares of the company's stock after buying an additional 467,401 shares during the period. Braidwell LP owned 2.55% of Harrow worth $30,431,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in HROW. JPMorgan Chase & Co. lifted its holdings in Harrow by 443.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company's stock valued at $10,717,000 after purchasing an additional 194,480 shares during the last quarter. Barclays PLC boosted its position in shares of Harrow by 301.9% during the 3rd quarter. Barclays PLC now owns 52,593 shares of the company's stock worth $2,365,000 after acquiring an additional 39,506 shares in the last quarter. Brookstone Capital Management acquired a new position in Harrow during the 4th quarter worth approximately $275,000. SG Americas Securities LLC raised its position in Harrow by 158.5% in the fourth quarter. SG Americas Securities LLC now owns 30,689 shares of the company's stock valued at $1,030,000 after purchasing an additional 18,815 shares during the last quarter. Finally, Sonora Investment Management Group LLC acquired a new stake in Harrow during the 4th quarter worth approximately $518,000. Institutional investors and hedge funds own 72.76% of the company's stock.

Harrow Stock Performance

NASDAQ HROW traded up $0.81 during trading hours on Friday, reaching $24.40. 1,281,092 shares of the company were exchanged, compared to its average volume of 510,015. Harrow, Inc. has a 1 year low of $11.39 and a 1 year high of $59.23. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The business's 50 day simple moving average is $24.79 and its 200-day simple moving average is $32.67. The stock has a market capitalization of $895.11 million, a P/E ratio of -25.96 and a beta of 0.41.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.40). Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The firm had revenue of $47.83 million during the quarter, compared to the consensus estimate of $57.00 million. On average, equities research analysts expect that Harrow, Inc. will post -0.53 earnings per share for the current year.

Wall Street Analyst Weigh In

HROW has been the topic of a number of recent analyst reports. B. Riley dropped their price target on shares of Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. HC Wainwright reiterated a "buy" rating and set a $57.00 price target on shares of Harrow in a research note on Monday, March 31st.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.